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Studies of the immune mechanisms of allograft rejection have predominantly focused on the adaptive immune system that
includes T cells and B cells. Recent investigations into the innate immune system, which recognizes foreign antigens through
more evolutionarily primitive pathways, have demonstrated a critical role of the innate immune system in the regulation of the
adaptive immune system. Innate immunity has been extensively studied in its role as the host’s ﬁrst-line defense against microbial
pathogens; however, it is becoming increasingly recognized for its ability to also recognize host-derived molecules that result
from tissue damage. The capacity of endogenous damage signals acting through the innate immune system to lower immune
thresholds and promote immune recognition and rejection of transplant grafts is only beginning to be appreciated. An improved
understanding of these pathways may reveal novel therapeutic targets to decrease graft alloreactivity and increase graft longevity.
1.AdaptiveandInnateImmune Responses
Alloantigen-speciﬁc T cells and B cells cause acute cellular
and humeral rejection through the recognition of graft
antigen by highly evolved immune receptors. These recep-
tors, T cell receptors and immunoglobulins, are capable
of recognizing an immense variety of antigens due to
their numerous encoding genes and due to the process
of somatic rearrangement of their encoding DNA. The
immense diversity of the cell receptors also predicates that
for a novel antigen, only a limited pool of lymphocytes will
have speciﬁcity towards that antigen. Consequently, in order
to conduct an eﬀective immune response, intense expansion
of antigen-speciﬁc lymphocytes is required. Because this
expansion may take several days, a more immediate defense
systemisalsorequiredtoaddressmicrobialinvasionsthatare
capable of rapid progression.
The innate immune system has come to the forefront
of immunological research with the discovery of Toll-like
receptors (TLRs) (reviewed in [1, 2]) along with the appre-
ciation that the context in which the antigen is recognized
is critical for promoting the immune response [3]. TLRs are
pattern recognition receptors (PRRs) that are expressed on
both nonlymphoid and lymphoid tissues, especially antigen-
presenting cells such as dendritic cells and macrophages.
Their ligation initiates intracellular signal transduction cas-
cades that lead to NF-κB activation and the upregulation
of the adhesion molecules, costimulatory molecules and
cytokines that are essential to immune activation [4, 5].
Characterization of the ligands and function of the various
TLRs has revealed that the innate pathways are critical to the
development of a robust adaptive immune response [1–3, 6–
9].
Unlike the immensely variable antigen recognition epi-
topes of T cell receptors and antibodies, TLRs have a ﬁxed
genomic structure and are capable of binding a limited
repertoire of ligands. Some of the resultant lack of variability
is overcome by the presence of multiple receptor types; for
example, there are currently 13 TLRs identiﬁed in mice and
humans. Despite their limited antigen recognition capability,
their conservation between evolutionarily distant species
hints that they may bind molecules that are indispensible
to microbes such that they cannot be mutated or ablated.
The beneﬁt of the TLR ﬁxed receptor structure is that a large
numberofinnateimmunecellscanrecognizeapathogenand
respond immediately.2 Journal of Transplantation
2. Exogenous andEndogenous TLR Ligands
TLRs have been identiﬁed with aﬃnities for molecules
associated with infection and tissue injury. However, their
ability to recognize pathogen-associated molecular patterns
(PAMPs) is best described. Some TLRs (TLR1, −2, −4, −5
and −6) are located on the outer cell membrane and recog-
nize microbial molecules derived from bacteria, fungus, and
parasites (reviewed by Akira et al., 2006 [1]) (Figure 1). For
example, TLR2 recognizes bacterial peptidoglycan, fungal
phospholipomannan, and Trypanosomal tGPI-mutin and
TLR4 recognizes bacterial lipopolysaccharide (LPS), fungal
mannan, and Trypanosomal Glycoinositol phospholipids.
OtherTLRs(TLR3, −7, −8and, −9)arelocatedwithinthein
the endosomal/lysosomal compartment and bind bacteria-
and virus-derived nucleic acids. For example, TLR3 binds
viral double-stranded RNA, TLR7 and TLR8 bind viral
single-stranded RNA, and TLR9 binds bacterial and viral
double-stranded DNA.
TLRs share homology with the Type I transmem-
b r a n eT o l lr e c e p t o rd i s c o v e r e di nt h ef r u i tﬂ y( Drosophila
melanogaster) initially identiﬁed for its role in controlling
dorsal-ventral polarity during embryogenesis [10]. It was
later discovered that Toll also induces production of antimi-
crobial peptides in response to fungal infection in adult
fruit ﬂies [11]. Considering the role of the Toll receptor
in development as well as primitive innate immunity, it
is not surprising that TLRs have endogenous ligands in
addition to microbial ligands. Endogenous TLR ligands
arising from tissue damage are termed damage-associated
molecular patterns or “DAMPs”, and they are becoming
increasingly recognized for their role in immune regulation
(Figure 1)[ 12–14].
More than 20 DAMPs have been described as stimulants
for TLRs [15]. Examples include heat-shock protein 60
(Hsp60), Hsp70, surfactant protein A, β-defensin 2 high-
mobility-group box 1 protein (HMGB1), and extracellular
matrix molecules such as hyaluronan, ﬁbronectin, and and
heparan sulfate [16, 17]. Some controversy exists with
regards to potential contamination of DAMPs with PAMPs
(e.g., LPS) resulting in false positive results of TLR stimula-
tion[18–20].Thisisespeciallyrelevanttoproteinstimulators
that have been synthesized from bacterial recombinant
technology. Nonetheless, there is accumulating evidence for
the role of DAMPs in shaping the overall immune response
especially when derived from stressed, injured, or necrotic
cells [21, 22].
While multiple TLRs exist, they share common intra-
cellular signaling pathways [4]. These include myeloid
diﬀerentiation primary response protein (MyD88), through
which all TLRs signal with the exception of TLR3, which
utilizes TRIF(Toll/IL-1R domain–containing adaptor induc-
ing IFN-α)[ 5]. Signal transduction pathways though both
MyD88 and TRIF have been described for TLR4 [5].
These pathways converge with the activation of NFκB,
which results in the transcription of multiple immune
stimulatory genes involved in immune cell development,
maturation and, cytokine production and proliferation
[23, 24].
3. TLRs inTransplantation
Several recent studies have highlighted the importance of
the innate immune system in allograft rejection in mouse
and human transplantation. In a minor antigen mismatch
model of graft rejection using HY-mismatched skin grafts,
MyD88knockoutrecipientsshowedtransplantsurvival>100
days whereas wild-type recipients rejected skin allografts at
a median of 16 days [25]. Interestingly, selective deletion
of TLR2 alone (TLR2 knockout hosts) only slightly pro-
longed skin allograft survival, and deletion of TLR4 (TLR4
knockout hosts) did not prolong skin allograft survival
[25]. These results imply that other MyD88-dependent
pathways contribute to alloimmunity (e.g., IL-1) or that
signiﬁcant redundancy in the signaling pathways exists.
In contrast, MyD88 deﬁciency does not prolong survival
of fully mismatched allogeneic skin and heart transplants
[26]. However, in both the minor and major mismatch
experiments, MyD88 deﬁciency leads to a defect in Th1-
dependent alloimmunity [25, 26]. This suggests that the
MyD88 pathways skew the immune response towards Th1-
type immunity and is suﬃcient to mediate allograft rejection
when only minor antigen mismatches are present. However,
thiseﬀectisoutweighedbythestrongerimmunologicstimuli
of a full antigen mismatch.
Polymorphisms of TLR4 at Asp299Gly and Thr399Ile
cause endotoxin hyporesponsiveness, and these mutations
arerelativelycommoninthehumanpopulation[27].Kidney
transplant recipients who carry these TLR4 polymorphisms
have been noted to have fewer episodes of acute rejection
[28].ThissameTLR4polymorphismsdecreasetheincidence
of acute allograft rejection when present in lung transplant
donors, but not recipients [29]. A trend toward reduced
acute graft-versus- host disease following bone marrow
transplantation is noted when either the bone marrow donor
or recipient carries these polymorphisms, but the eﬀect is
greater when the recipient carries the TLR4 mutation [30].
Interestingly, hepatitis C-infected liver transplant recipients
with the TLR4 Asp299Gly mutation are found to have
signiﬁcantly worse long-term graft outcomes than recipients
lacking this mutation [31]. Overall, these studies provide
clinicalsubstantiationoftheexperimentallyobservedimpor-
tance of TLR4 in graft rejection.
4. InnateImmune Activationin
Transplantation-TissueInjury
Tissue injury during the pre- and posttransplant periods
may result from a multitude of mechanisms, and these
factors contribute to end-organ damage and aﬀect allograft
survival (Figure 2). Immune activation in the donor organ
during the pretransplant period begins with brain death and
the neuropathology associated with brainstem herniation.
As the medulla becomes ischemic, vagal activity ceases,
resulting in massive sympathetic outﬂow and high levels
of catecholamines. In addition to aﬀecting cardiac function
by stimulating tachycardia, hypertension, and dysrhythmia,
catecholamine release results in peripheral vasoconstric-















Figure 1: Infection and cell injury result in the production of PAMPs and DAMPs that promote the inﬂammatory response via TLRs located
on the cell membrane and within endosomes. Cytoplasmic PAMPs activate similar pathways by binding to NOD1 and NOD2.
the resolution of the catecholamine storm, the sympathetic
toneislost,resultinginvasodilatationandreperfusioninjury
to tissue followed by hypotension that can again cause organ
hypoperfusion. Brain death also results in an outpouring of
inﬂammatory cytokines [32], including IL-6 that has been
shown to correlate with worse recipient outcomes in the
setting of kidney transplantation [33].
In addition to the release of a multitude of cytokines,
acute brain injury has also been shown to up-regulate
endogenous innate immune activators Hsp70 [34]a n d
HMGB1 [35], as well as to cause the release of ﬁbrinogen
fragments [36]. Interestingly, while inﬂammation derived
from acute brain injury has been shown to be dependent on
MyD88, it has been shown to be independent of TLR2 and
TLR4, the receptors identiﬁed for the majority of DAMPs
[37]. Potentially, alternative pathways of MyD88-mediated
TLR signaling act to transduce these inﬂammatory signals.
The eﬀect of adverse proinﬂammatory and neurophys-
iologic events on the donor organ quality that arise from
brain death has led to the initiation of several studies
investigating preprocurement donor cytoprotective thera-
pies.Forexample,dopaminepretreatmenthasbeenobserved
to protect rat kidney allografts from cold ischemic injury
[38, 39], potentially by augmenting the expression of the
heat-shock protein, heme-oxygenase-1 [40, 41]. Recently,
in a randomized controlled study of human kidney trans-
plantation, donor pretreatment with dopamine signiﬁcantly
improved early graft function [42]. Donor pretreatment
with intraperitoneal glutamine in the rat kidney transplant
model diminishes early structural damage due to prolonged
preservation reperfusion injury [43]. Preconditioning with
oral vitamin E has also been noted to improve post-
ischemic recovery of systolic function following rat cardiac
transplantation [44]. These experimental therapies suggest
future potential to improve the viability of deceased donor
organs.
Necrotic cell death that can result from cold ischemia,
ischemia-reperfusion injury, and surgical trauma has been
shown to elicit a strong inﬂammatory response [45]. For
example, necrotic or damaged cells release HMGB1, a
chromatin-binding protein that can act as an endogenous
activator of TLR4 and cell signaling mediated by MyD88
when released extracellularly [46, 47]. HMGB1 can be
secreted by activated monocytes and macrophages and is
passively released during cellular necrosis. HMGB1 is a
potentpromoterofinﬂammationthatresultsinthereleaseof
cytokines and chemokines that promote inﬂammatory tissue
damage [47, 48].
Surgical trauma to the donor organ incurred during
procurement and to the donor and recipient during the
transplantation procedure can release DAMPs and activate
the immune system. However, probably the most signiﬁcant
contributor to either organ or end-organ injury during
transplantation is the ischemic injury caused by cold storage
followedbythewarmreperfusionatthetimeofengraftment.
The association between rejection and increased duration of
cold ischemia has been well established [49]. Modulation
of reperfusion damage may result in improved allograft
function following transplantation. For example, ﬁngolimod
(FTY720), a sphingosine-1-phosphate receptor agonist that
interferes with lymphocyte traﬃcking, provides tubular
epithelial protection in the presence of severe preservation-
reperfusion injury in a rat kidney transplant model [50].
Reperfusion of ischemic organs results in activation
of inﬂammatory pathways and complement cascades that
increase graft immunogenicity [51–53]. Murine models of
ischemia-reperfusion injury provide evidence for the role of








Figure 2: Liver injury during transplantation can convert an immunologically quiescent organ to an inﬂammatory organ that promotes
acute rejection.
kidney reperfusion injury, both TLR2 and TLR4 expressions
are increased amongst renal epithelial cells [54]. Similarly,
in models of myocardial ischemia-reperfusion injury, mice
deﬁcient in TLR4 develop smaller areas of myocardial





Following transplantation, the liver remains susceptible
to additional sources of innate immune activation from
infection. Microorganisms, either from bacteria transloca-
tion across injured bile duct epithelium or from post-
operative infections in the form of bilomas, abscesses,
wound infections, and viral infections, may initiate inﬂam-
matory cascades that adversely aﬀect the allograft survival.
Inﬂammatory responses due to systemic viral infections
such as cytomegalovirus (CMV) [57], herpes viruses [58],
adenovirus [59], and polyomaviruses [60]; moreover viral
infections within the transplanted organ such as hepatitis
B[ 61] and hepatitis C liver infections [62], adenovirus
heart infection [63], and CMV graft infections [58, 64,
65] have been associated with adverse clinical outcomes.
In experimental models, systemic viral infections are also
known to result in allograft rejection and disruption of
immunoregulation [66–70].
The activation of innate immune pathways is likely
important in directing the initial activation of the allograft
rejection response, but they also may disrupt established
immunetolerance.StimulationofTLRreceptorswithLPSor
CpGDNAhasbeenshowntoabrogatetransplanttolerogenic
regimens in both skin and heart transplant models [71, 72].
While the mechanism of the break in tolerance is not well
understood, it may be caused by the failure of graft-reactive
CD8+ T cells to undergo apoptosis [71], the blockade of Treg
function [73], or the accumulation of Tregs at the graft site
[71].
6. FutureArea of Investigation
Although multiple pathways by which DAMPs may activate
innate immune responses have been discovered, additional
pathways await discovery. Diﬀerent routes of cell death
may release divergent signals to the immune system. For
example, programmed cell death through apoptosis may
release diﬀerent immune mediators than cells that died from
stress or injury. Evaluation of lysates of otherwise healthy
cells made necrotic by Dounce-lysis or freeze thaw cycles,
demonstratesthattheycontainfactorsthatareabletoinduce
NF-κB via TLR2 present on ﬁbroblasts and macrophages
[74]. The activating agent must be present in healthy cells
at the time of lysis and does not require de-novo synthesis.
In contrast, cells made apoptotic through irradiation did not
induce NF-κB[ 74]. This demonstrates that not all dead cells
are equally stimulatory and that genetic programs may exist
to sequester DAMPs when programmed cell death occurs.
Evaluation of a diﬀerent cell fraction may also illuminate
a larger variety of DAMPs. For example, mitochondria
are intracellular organelles with bacterial origins and have
recently been discovered to harbor DAMPs. Cells made
necrotic through freeze-thaw cycling release mitochondrial
N-formyl peptides that stimulate IL-8 production by mono-
cytes [75]. Similar to bacteria, mitochondrial DNA is rich
in CpG dinucleotides which are the ligand for TLR9 in
monocytes [1]. In addition, DAMPs can represent organic
products of metabolism. For example, uric acid has been
recently shown to elicit an acute inﬂammatory response to
sterile cell death in mice [76].
New research has implicated many DAMPs to be
molecules that increase the eﬃcacy of PAMPs rather than
being true TLR ligands themselves [15]. Further research
into the precise mechanism of DAMP-TLR binding needsJournal of Transplantation 5
to be done to conﬁrm which DAMPs are ligands and which
only facilitate the binding of true ligands. It also remains
unclear whether receptor competition exists when multiple
DAMPs are present simultaneously, as would be expected at
sitesofinjury.Similarly,theremayexistcompetitionbetween
DAMPs and PAMPs for TLRs. Alternatively, DAMP- and
PAMP-mediated cell signaling may synergize.
Additional pathways of molecular signaling that con-
tribute to the propagation of innate immune signals need
to be further investigated. For example, several microRNAs
(miRNAs) have been found to regulate the innate response
to pathogens [77]. miRNAs are a recently described family
of small, noncoding RNAs that regulate gene expression
by interfering with protein translation and by targeting
messenger RNA for degradation. Already there is evidence
that miRNA-146 serves as a negative feedback inhibitor of
TLR signal transduction [78] and that miRNA-125b and
miRNA-155 regulate the stimulation of TNF-α production
by the innate immune system [79].
The role of non-TLR innate receptor families in the
regulation of the immune response is also just beginning
to be uncovered. For example, the NOD-LRR and CARD-
helicase proteins, which comprise a huge family of recep-
tors involved in pathogen recognition [80, 81], have only
recently been deﬁned. Unlike TLRs, which are imbedded
in cell surface or lysosomal-endosomal membranes, these
receptors are cytosolic and recognize pathogen-associated
molecules within the cytosol. Like TLRs they can produce
an inﬂammatory response driven by NF-κB thus, resulting in
immune activation. One member of the NLR family, NLRP3
(NLR family, pyrin domain containing 3) has been found to
be involved with the sterile inﬂammatory response caused by
necrotic cells [82] and in the stimulation of IL-1β secretion
triggered by cholesterol crystals [83].
We need to further our understanding of the innate
immune pathways that contribute to the alloimmune
response leading to acute, as well as chronic, graft rejection.
These studies need to look at the contributions of both
exogenous and endogenous innate immune stimulants and
how these two sources of ligands may function in synergistic
activation pathways. Also, some ligands may function as
competitiveinhibitors,andtheirroleinimmunesuppression
could provide a novel route of immunosuppression. Finally,
targeting the innate pathways can be instituted at multiple
timepoints in the transplant setting: in the donor begin-
ning with brain death, during procurement, cold storage,
reperfusion, immediately postoperatively, or in the late
postoperative period in the setting of infection or chronic
rejection. How and when to address these pathways has yet
to be determined.
7. Summary
As our understanding of the immune systems grows, the
mechanisms by which eﬀective allograft rejection responses
are initiated become increasingly complex. The role of
allogeneic T cells and B cells in precipitating rejection has
been well established; however, more recent investigations
have highlighted the way in which innate immune responses
may skew or direct adaptive immunity. The chief among
these pathways appears to be the TLRs. Although evo-
lutionarily primitive, these receptors appear to propagate
innate immune activation and to facilitate activation of
adaptive immunity in ways that are only presently being
elucidated. In the case of allograft immunity, initiation of
innate immune signals through DAMPs and PAMPs can
activate potent immune stimulatory pathways that increase
allograft vulnerability to the host immune system. Strategies
for successful modulation of these signals will likely improve
allograft outcomes and allow for the minimization of
systemic immunosuppressive therapies.
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